enVVeno Medical Corporation (NVNO) Financial Ratios
12 years of historical data (2014–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
0.22
↑+9574% vs avg
5yr avg: 0.00
30Y Low0.0·High0.0
ROE
↓
-56.2%
-5% vs avg
5yr avg: -53.5%
30Y Low-226%·High-49%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NVNO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
enVVeno Medical Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7M | $189069 | $42259 | $51616 | $46752 | $46697 | $9117 | $7081 | $11285 | — | — |
| Enterprise Value | $4M | $-2175931 | $-647741 | $-2166384 | $-2792248 | $-52675068 | $-8444819 | $-443517 | $-2729360 | — | — |
| P/E Ratio → | -0.30 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | 0.23 | 0.06 | — | — |
| P/B Ratio | 0.22 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NVNO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | -14.20 | -14.63 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
NVNO Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -56.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | 100.0% | 100.0% | -32.4% | -22.3% |
| Operating Margin | — | — | — | — | — | — | — | -24566.5% | -4210.5% | -1445.9% | -592.8% |
| Net Profit Margin | — | — | — | — | — | — | — | -24406.7% | -6991.5% | -1845.8% | -749.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -56.2% | -56.2% | -49.4% | -55.4% | -53.0% | -53.7% | -225.9% | -503.9% | -640.5% | — | — |
| ROA | -52.3% | -52.3% | -46.6% | -52.1% | -49.7% | -48.4% | -130.8% | -218.1% | -451.7% | -389.8% | -252.8% |
| ROIC | -47.3% | -47.3% | -41.8% | -47.4% | -99.5% | -7764.0% | — | — | — | — | — |
| ROCE | -59.5% | -59.5% | -52.9% | -57.8% | -51.8% | -53.2% | -205.1% | -427.1% | -385.7% | — | — |
NVNO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $3M exceeds total debt of $700000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.12 | 0.87 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.09 | -0.02 | -0.05 | -0.07 | -0.97 | -1.19 | -0.46 | -1.35 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -2443.30 | -8171.99 | -0.90 | -3.06 | -95.53 |
Net cash position: cash ($3M) exceeds total debt ($700000)
NVNO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
enVVeno Medical Corporation's current ratio of 13.58x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 34.23x to 13.58x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.58 | 13.58 | 20.88 | 34.23 | 25.78 | 34.83 | 3.00 | 0.76 | 1.86 | 0.02 | 0.19 |
| Quick Ratio | 13.58 | 13.58 | 20.88 | 34.23 | 25.78 | 34.83 | 3.00 | 0.76 | 1.86 | 0.02 | 0.15 |
| Cash Ratio | 13.30 | 13.30 | 20.60 | 33.85 | 25.52 | 34.64 | 2.93 | 0.70 | 1.80 | 0.01 | 0.03 |
| Asset Turnover | — | — | — | — | — | — | — | 0.01 | 0.05 | 0.19 | 0.44 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | 10.58 |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | 62.65 | 30.42 | 92.77 |
NVNO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
enVVeno Medical Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $589000 | $13993 | $10042 | $9167 | $7086 | $1054 | $515 | $306 | $316 | $358 |
Peer Comparison
Compare NVNO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NVNOYou | $7M | -0.3 | — | — | — | — | -56.2% | -47.3% | — |
 VNRX | $12M | -0.5 | — | — | 100.0% | -1228.6% | — | — | — |
 TELA | $41M | -0.8 | — | — | 67.1% | -49.2% | -159.9% | -151.6% | — |
 NVCR | $2B | -14.7 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ANGO | $466M | -13.5 | — | — | 53.9% | -13.7% | -17.5% | -22.9% | — |
 ELMD | $223M | 31.3 | 19.2 | 20.1 | 78.1% | 15.1% | 17.2% | 25.6% | 0.0 |
 LMAT | $2B | 42.8 | 33.4 | 33.0 | 71.5% | 27.2% | 15.8% | 9.7% | 2.4 |
 ATRC | $1B | -109.5 | 73.2 | 27.6 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 BSX | $80B | 27.8 | 24.2 | 21.9 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 MDT | $98B | 21.1 | 14.1 | 18.8 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 ABT | $147B | 11.0 | 15.4 | 23.1 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
| Healthcare Median | — | 21.9 | 14.2 | 18.5 | 64.3% | -5.0% | -34.0% | -11.0% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
See NVNO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NVNO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NVNO vs VNRX
Side-by-side business, growth, and profitability comparison vs VolitionRx Limited.
Start ComparisonNVNO — Frequently Asked Questions
Quick answers to the most common questions about buying NVNO stock.
What is enVVeno Medical Corporation's P/E ratio?
enVVeno Medical Corporation's current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
What is enVVeno Medical Corporation's ROE?
enVVeno Medical Corporation's return on equity (ROE) is -56.2%. The historical average is -82.3%.
Is NVNO stock overvalued?
Based on historical data, enVVeno Medical Corporation is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.